The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis

Background. Previous studies have shown impaired fibrinolysis in multiple sclerosis (MS) and implicated extracellular proteolytic enzymes as important factors in demyelinating neuroinflammatory disorders. Tissue-type plasminogen activator (t-PA) and its inhibitor (PAI-1) are key molecules in both fi...

Full description

Bibliographic Details
Main Authors: Maja Živković, Nada Starčević Čizmarević, Luca Lovrečić, Inge Klupka-Sarić, Aleksandra Stanković, Iva Gašparović, Polona Lavtar, Evica Dinčić, Ljiljana Stojković, Gorazd Rudolf, Saša Šega Jazbec, Olivio Perković, Osman Sinanović, Juraj Sepčić, Miljenko Kapović, Borut Peterlin, Smiljana Ristić
Format: Article
Language:English
Published: Hindawi Limited 2014-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.1155/2014/362708
id doaj-9df6063e8ff74958bf6fac307b99b56c
record_format Article
spelling doaj-9df6063e8ff74958bf6fac307b99b56c2020-11-24T22:43:34ZengHindawi LimitedDisease Markers0278-02401875-86302014-01-01201410.1155/2014/362708362708The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple SclerosisMaja Živković0Nada Starčević Čizmarević1Luca Lovrečić2Inge Klupka-Sarić3Aleksandra Stanković4Iva Gašparović5Polona Lavtar6Evica Dinčić7Ljiljana Stojković8Gorazd Rudolf9Saša Šega Jazbec10Olivio Perković11Osman Sinanović12Juraj Sepčić13Miljenko Kapović14Borut Peterlin15Smiljana Ristić16Laboratory for Radiobiology and Molecular Genetics, “Vinča” Institute of Nuclear Sciences, University of Belgrade, 11000 Belgrade, SerbiaDepartment of Biology and Medical Genetics, School of Medicine, University of Rijeka, 51000 Rijeka, CroatiaClinical Institute of Medical Genetics, University Medical Centre, 1000 Ljubljana, SloveniaDepartment of Neurology, School of Medicine, University of Mostar, 88000 Mostar, Bosnia and HerzegovinaLaboratory for Radiobiology and Molecular Genetics, “Vinča” Institute of Nuclear Sciences, University of Belgrade, 11000 Belgrade, SerbiaDepartment of Neurology, Clinical Hospital Center Rijeka, 51000 Rijeka, CroatiaClinical Institute of Medical Genetics, University Medical Centre, 1000 Ljubljana, SloveniaNeurology Clinic, Military Medical Academy, 11000 Belgrade, SerbiaLaboratory for Radiobiology and Molecular Genetics, “Vinča” Institute of Nuclear Sciences, University of Belgrade, 11000 Belgrade, SerbiaClinical Institute of Medical Genetics, University Medical Centre, 1000 Ljubljana, SloveniaDepartment of Neurology, University Medical Centre, 1000 Ljubljana, SloveniaDepartment of Neurology, Clinical Hospital Center Rijeka, 51000 Rijeka, CroatiaDepartment of Neurology, School of Medicine, University of Tuzla, 75000 Tuzla, Bosnia and HerzegovinaPostgraduate Studies, School of Medicine, University of Rijeka, 51000 Rijeka, CroatiaDepartment of Biology and Medical Genetics, School of Medicine, University of Rijeka, 51000 Rijeka, CroatiaClinical Institute of Medical Genetics, University Medical Centre, 1000 Ljubljana, SloveniaDepartment of Biology and Medical Genetics, School of Medicine, University of Rijeka, 51000 Rijeka, CroatiaBackground. Previous studies have shown impaired fibrinolysis in multiple sclerosis (MS) and implicated extracellular proteolytic enzymes as important factors in demyelinating neuroinflammatory disorders. Tissue-type plasminogen activator (t-PA) and its inhibitor (PAI-1) are key molecules in both fibrinolysis and extracellular proteolysis. In the present study, an association of the TPA Alu I/D and PAI-1 4G/5G polymorphisms with MS was analyzed within the Genomic Network for Multiple Sclerosis (GENoMS). Methods. The GENoMS includes four populations (Croatian, Slovenian, Serbian, and Bosnian and Herzegovinian) sharing the same geographic location and a similar ethnic background. A total of 885 patients and 656 ethnically matched healthy blood donors with no history of MS in their families were genotyped using PCR-RFLP. Results. TPA DD homozygosity was protective (OR = 0.79, 95% CI 0.63–0.99, P=0.037) and PAI 5G5G was a risk factor for MS (OR = 1.30, 95% CI 1.01–1.66, P=0.038). A significant effect of the genotype/carrier combination was detected in 5G5G/I carriers (OR = 1.39 95% CI 1.06–1.82, P=0.017). Conclusions. We found a significantly harmful effect of the combination of the PAI-1 5G/5G genotype and TPA I allele on MS susceptibility, which indicates the importance of gene-gene interactions in complex diseases such as MS.http://dx.doi.org/10.1155/2014/362708
collection DOAJ
language English
format Article
sources DOAJ
author Maja Živković
Nada Starčević Čizmarević
Luca Lovrečić
Inge Klupka-Sarić
Aleksandra Stanković
Iva Gašparović
Polona Lavtar
Evica Dinčić
Ljiljana Stojković
Gorazd Rudolf
Saša Šega Jazbec
Olivio Perković
Osman Sinanović
Juraj Sepčić
Miljenko Kapović
Borut Peterlin
Smiljana Ristić
spellingShingle Maja Živković
Nada Starčević Čizmarević
Luca Lovrečić
Inge Klupka-Sarić
Aleksandra Stanković
Iva Gašparović
Polona Lavtar
Evica Dinčić
Ljiljana Stojković
Gorazd Rudolf
Saša Šega Jazbec
Olivio Perković
Osman Sinanović
Juraj Sepčić
Miljenko Kapović
Borut Peterlin
Smiljana Ristić
The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis
Disease Markers
author_facet Maja Živković
Nada Starčević Čizmarević
Luca Lovrečić
Inge Klupka-Sarić
Aleksandra Stanković
Iva Gašparović
Polona Lavtar
Evica Dinčić
Ljiljana Stojković
Gorazd Rudolf
Saša Šega Jazbec
Olivio Perković
Osman Sinanović
Juraj Sepčić
Miljenko Kapović
Borut Peterlin
Smiljana Ristić
author_sort Maja Živković
title The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis
title_short The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis
title_full The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis
title_fullStr The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis
title_full_unstemmed The Role of TPA I/D and PAI-1 4G/5G Polymorphisms in Multiple Sclerosis
title_sort role of tpa i/d and pai-1 4g/5g polymorphisms in multiple sclerosis
publisher Hindawi Limited
series Disease Markers
issn 0278-0240
1875-8630
publishDate 2014-01-01
description Background. Previous studies have shown impaired fibrinolysis in multiple sclerosis (MS) and implicated extracellular proteolytic enzymes as important factors in demyelinating neuroinflammatory disorders. Tissue-type plasminogen activator (t-PA) and its inhibitor (PAI-1) are key molecules in both fibrinolysis and extracellular proteolysis. In the present study, an association of the TPA Alu I/D and PAI-1 4G/5G polymorphisms with MS was analyzed within the Genomic Network for Multiple Sclerosis (GENoMS). Methods. The GENoMS includes four populations (Croatian, Slovenian, Serbian, and Bosnian and Herzegovinian) sharing the same geographic location and a similar ethnic background. A total of 885 patients and 656 ethnically matched healthy blood donors with no history of MS in their families were genotyped using PCR-RFLP. Results. TPA DD homozygosity was protective (OR = 0.79, 95% CI 0.63–0.99, P=0.037) and PAI 5G5G was a risk factor for MS (OR = 1.30, 95% CI 1.01–1.66, P=0.038). A significant effect of the genotype/carrier combination was detected in 5G5G/I carriers (OR = 1.39 95% CI 1.06–1.82, P=0.017). Conclusions. We found a significantly harmful effect of the combination of the PAI-1 5G/5G genotype and TPA I allele on MS susceptibility, which indicates the importance of gene-gene interactions in complex diseases such as MS.
url http://dx.doi.org/10.1155/2014/362708
work_keys_str_mv AT majazivkovic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT nadastarceviccizmarevic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT lucalovrecic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT ingeklupkasaric theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT aleksandrastankovic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT ivagasparovic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT polonalavtar theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT evicadincic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT ljiljanastojkovic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT gorazdrudolf theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT sasasegajazbec theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT olivioperkovic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT osmansinanovic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT jurajsepcic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT miljenkokapovic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT borutpeterlin theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT smiljanaristic theroleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT majazivkovic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT nadastarceviccizmarevic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT lucalovrecic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT ingeklupkasaric roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT aleksandrastankovic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT ivagasparovic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT polonalavtar roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT evicadincic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT ljiljanastojkovic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT gorazdrudolf roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT sasasegajazbec roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT olivioperkovic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT osmansinanovic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT jurajsepcic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT miljenkokapovic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT borutpeterlin roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
AT smiljanaristic roleoftpaidandpai14g5gpolymorphismsinmultiplesclerosis
_version_ 1725695147451088896